{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-112235","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.912786+00:00","generated_at":"2026-05-30T08:53:55.653276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx Q3 revenue rose 27% to $13.4M; net loss widened to $13.1M","bullets":["US HF revenue $12.2M (+30% YoY) driven by territory expansion and new accounts.","Net loss of $13.1M ($0.57/share) vs $9.0M ($0.43/share) a year ago; SG&A expenses up 38%.","Active implanting centers reached 208, up 31% YoY; cash $100.2M after drawing $20M loan tranche.","CMS reassigned Barostim to MS-DRG 276, raising inpatient payment to ~$43,000 from $17-23K.","FY2024 revenue guidance narrowed to $50.5-51.5M (from $50-53M); operating expense guidance raised to ~$100M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-112235","json":"https://secwatch.observer/filing/0001104659-24-112235.json","markdown":"https://secwatch.observer/filing/0001104659-24-112235.md","text":"https://secwatch.observer/filing/0001104659-24-112235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924112235/0001104659-24-112235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465924112235/tm2427008d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:53:55.653276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}